GLOBAL HYPERTENSION FACTS

PREVALENCE

1 Billion
Estimated people worldwide have hypertension

GLOBAL INCIDENCE

60%
Expected increase in the global incidence of hypertension by 2025

CURRENT TREATMENTS

10 Million
Estimated people worldwide who have high blood pressure despite taking 2 or more medications

COST

~10% of all global healthcare spending is attributable to high blood pressure

U.S. HYPERTENSION FACTS

PREVALENCE

1 in 3 U.S. adults has high blood pressure

MORTALITY

~1,000
Deaths Per Day
List high blood pressure as a primary or contributing cause of death

CURRENT TREATMENTS

36 Million
U.S. adults with high blood pressure don’t have it under control

COST

$343 Billion
Projected total cost of High Blood Pressure by 2030

---


The information in this document is intended for use by media members and is not to be distributed to health care professionals. The products and technologies featured in this document are considered in development and are not available for use or sale in the United States.

© Boston Scientific Corporation. All rights reserved. Vessix Renal Denervation System is not available for sale in the US or JPN.
HYPERTENSION

- Hypertension, or high blood pressure, is a **chronic condition** in which the blood pressure in the arteries is higher than normal. This condition can put extra strain on the heart and circulatory system, which must work harder to circulate blood.

- Hypertension is a **major risk factor** for a variety of cardiovascular diseases, including coronary artery disease, heart failure, stroke and peripheral vascular disease. Hypertension accounts for an estimated 54 percent of all strokes and 47 percent of all ischemic heart disease globally.

- Hypertension affects more than a quarter of all adults and is the **leading attributable cause of death** worldwide. It is estimated that over 1 billion people worldwide have hypertension.

- The **global incidence** of hypertension among adults is expected to increase 60% by 2025.

- Approximately 10% of all global healthcare spending is attributable to high blood pressure.

- The annual worldwide **cost of hypertension** is estimated at $370 billion.

---

UNCONTROLLED HYPERTENSION

- Despite the widespread availability of antihypertensive medications, the blood pressure of many patients remains high and uncontrolled.

- This may be due to non-adherence to medication, diet and lifestyle causes, interfering medications, or underlying diseases.

- Approximately **45%-81%** of patients with hypertension have uncontrolled hypertension.

- It is estimated that over **10 million people** worldwide have from high blood pressure despite taking 2 or more medications.

---

**Uncontrolled blood pressure is a substantial problem within the hypertensive population**

RESISTANT HYPERTENSION

BACKGROUND INFORMATION

RESISTANT HYPERTENSION

• Resistant hypertension is a subset of patients with uncontrolled hypertension; “resistant” patients have hypertension despite adherence to 3 or more antihypertensive drugs including a diuretic.

• Resistant hypertension is defined as office blood pressure >140/90 mm Hg or 130/80 mm Hg in patients with diabetes or chronic kidney disease despite use of three or more antihypertensives.

• Resistant hypertension is also office blood pressure at goal with four or more antihypertensive medications required to control blood pressure.

• 12% of all treated hypertension patients have treatment resistant hypertension.

Resistant hypertension is a subset of uncontrolled hypertension:

• Underlying causes of resistant hypertension include excessive sympathetic nervous system activity.

• Higher rate of cardiovascular events in patients with uncontrolled blood pressure contributes to substantial economic burden of resistant hypertension to both the healthcare system and the families of patients with resistant hypertension.

• Complications of pharmaceutical therapy are the biggest impact to quality of life in patients with resistant hypertension. In most cases, clear documentation of attempts at blood pressure control is required prior to authorizing treatment for resistant hypertension.


THE VESSIX GLOBAL CLINICAL PROGRAM

- Boston Scientific collaborates with researchers, physicians and hospital systems worldwide to advance the science of cardiovascular medicine. A key component of that commitment is the Vessix Global Clinical Program, which includes both the REDUCE-HTN and RELIEVE Clinical Series.
- The REDUCE-HTN Clinical Series plans to enroll more than 1,200 resistant hypertension patients worldwide and already includes the largest cohort of patients studied following treatment with a multi-electrode renal denervation system.
- The RELIEVE Clinical Series includes pre-clinical, clinical and investigator initiated research evaluating the Vessix System* technology in additional disease states including end-stage renal disease, heart failure, atrial fibrillation and diabetes.

Vessix™ Clinical Program

REDUCE Clinical Series

- Studies evaluating the Vessix System technology in the currently defined hypertension space:
  - REDUCE-HTN FIM Study
  - REDUCE-HTN Post Market Study
  - REDUCE-HTN Global Pivotal Study
  - REDUCE-HTN Regional Regulatory Approval Studies
  - REDUCE-HTN EU Post Market Trial

RELIEVE Clinical Series

- Includes pre-clinical, clinical and investigator initiated research evaluating the Vessix System technology in additional disease states:
  - RELIEVE - End Stage Renal Disease
  - RELIEVE - Heart Failure
  - RELIEVE - Atrial Fibrillation
  - RELIEVE - Diabetes

*Investigational device, limited by applicable law to investigational use only and not available for sale.